Increased Demand of Obese Women for Protectins, Maresin, and Resolvin D1 in the Last Trimester of Pregnancy.
DHA
EPA
inflammation
maresin
pregnancy
protectin
resolvins
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
received:
11
09
2023
revised:
05
10
2023
accepted:
10
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Pregnancy is a physiological state during which inflammation occurs. This complex biological response is necessary for the implantation process as well as delivery. In turn, its suppression during gestation favors the normal course of the pregnancy. Therefore, the presence of pro-resolving mediators, EPA and DHA derivatives, The aim of this study was to investigate the changes in the levels of anti-inflammatory resolvins and their precursors in different trimesters of pregnancy with consideration of the women's weight, including overweight and obese women before pregnancy. A total of 78 women participated in this study; the mean age and BMI before pregnancy were 32.3 ± 5.52 and 27.73 ± 6.13, respectively. The patients were divided into two groups, considering their BMI before pregnancy. The extraction of eicosanoids was performed by high-performance liquid chromatography. The results obtained were subjected to statistical analysis. The levels of all studied parameters showed statistically significant differences between the study group (SG) and the control group (CG) in the different trimesters of pregnancy. Over the course of pregnancy, the levels of protection (PDX), maresin, resolvins (RvD1, RvE1), and their precursors differed in relation to the trimester of pregnancy and the division into groups considering the correct body weight before pregnancy. Overweight or obese women had significantly lower levels of RvE1 in the third trimester and their precursors compared to normal-weight women. While the levels of PDX and RvD1 were significantly higher, this may be due to both a lower intake of products rich in omega-3 fatty acids by obese women and an increased need of obese women's bodies to quench chronic inflammatory processes associated with obesity. Both EPA and DHA derivatives are involved in calming down inflammation during pregnancy, which was observed.
Sections du résumé
BACKGROUND
BACKGROUND
Pregnancy is a physiological state during which inflammation occurs. This complex biological response is necessary for the implantation process as well as delivery. In turn, its suppression during gestation favors the normal course of the pregnancy. Therefore, the presence of pro-resolving mediators, EPA and DHA derivatives, The aim of this study was to investigate the changes in the levels of anti-inflammatory resolvins and their precursors in different trimesters of pregnancy with consideration of the women's weight, including overweight and obese women before pregnancy.
METHODS
METHODS
A total of 78 women participated in this study; the mean age and BMI before pregnancy were 32.3 ± 5.52 and 27.73 ± 6.13, respectively. The patients were divided into two groups, considering their BMI before pregnancy. The extraction of eicosanoids was performed by high-performance liquid chromatography. The results obtained were subjected to statistical analysis. The levels of all studied parameters showed statistically significant differences between the study group (SG) and the control group (CG) in the different trimesters of pregnancy. Over the course of pregnancy, the levels of protection (PDX), maresin, resolvins (RvD1, RvE1), and their precursors differed in relation to the trimester of pregnancy and the division into groups considering the correct body weight before pregnancy.
RESULTS
RESULTS
Overweight or obese women had significantly lower levels of RvE1 in the third trimester and their precursors compared to normal-weight women. While the levels of PDX and RvD1 were significantly higher, this may be due to both a lower intake of products rich in omega-3 fatty acids by obese women and an increased need of obese women's bodies to quench chronic inflammatory processes associated with obesity.
CONCLUSIONS
CONCLUSIONS
Both EPA and DHA derivatives are involved in calming down inflammation during pregnancy, which was observed.
Identifiants
pubmed: 37892415
pii: nu15204340
doi: 10.3390/nu15204340
pmc: PMC10609750
pii:
doi:
Substances chimiques
resolvin D1
0
Fatty Acids, Omega-3
0
CD59 Antigens
0
Docosahexaenoic Acids
25167-62-8
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Postepy Hig Med Dosw (Online). 2010 Mar 17;64:115-32
pubmed: 20354260
Lipids Health Dis. 2013 Jun 15;12:89
pubmed: 23767972
Sci Rep. 2017 Nov 16;7(1):15724
pubmed: 29146976
Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):24-41
pubmed: 26219838
Nutrients. 2015 Mar 18;7(3):2001-14
pubmed: 25793632
Arch Med Sci. 2017 Jun;13(4):851-863
pubmed: 28721154
Blood. 2008 Aug 1;112(3):848-55
pubmed: 18480426
Mediators Inflamm. 2017;2017:5489523
pubmed: 28655971
J Immunol. 2007 Mar 15;178(6):3912-7
pubmed: 17339491
Curr Opin Genet Dev. 2017 Dec;47:24-32
pubmed: 28850905
Theranostics. 2019 Sep 19;9(22):6719-6733
pubmed: 31588246
Inflamm Res. 2020 Sep;69(9):869-881
pubmed: 32488315
Allergol Int. 2015 Jan;64(1):27-34
pubmed: 25572556
J Lipid Res. 2013 Aug;54(8):2247-2254
pubmed: 23723388
Int J Mol Sci. 2019 Sep 07;20(18):
pubmed: 31500240
Reproduction. 2015 Feb;149(2):171-8
pubmed: 25504868
J Toxicol Environ Health A. 2014;77(21):1281-4
pubmed: 25268554
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14983-8
pubmed: 22927428
Nat Rev Immunol. 2016 Jan;16(1):51-67
pubmed: 26688348
Nutrients. 2020 May 20;12(5):
pubmed: 32443667
Mol Aspects Med. 2018 Dec;64:1-17
pubmed: 28802833
Redox Biol. 2015 Dec;6:297-310
pubmed: 26298204
Orv Hetil. 2019 Aug;160(32):1247-1259
pubmed: 31387374
Front Pharmacol. 2016 Sep 07;7:274
pubmed: 27656142
Clin Sci (Lond). 2018 Oct 29;132(20):2221-2239
pubmed: 30287519
Diabetes. 2013 Jun;62(6):1945-56
pubmed: 23349501
Postepy Hig Med Dosw (Online). 2017 Feb 15;71(0):110-117
pubmed: 28258671
FASEB J. 2009 Jul;23(7):2165-75
pubmed: 19255255
J Immunol. 2015 Mar 1;194(5):2330-7
pubmed: 25637017
Front Pharmacol. 2018 Nov 14;9:1273
pubmed: 30487747
Am J Physiol Cell Physiol. 2014 Jan 15;306(2):C178-85
pubmed: 24259417
Biochem J. 2011 Jul 15;437(2):185-97
pubmed: 21711247
Reproduction. 2012 Dec;144(6):661-8
pubmed: 23028125
Bioorg Chem. 2016 Aug;67:130-8
pubmed: 27376460
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):660-664
pubmed: 30641785
Curr Pharm Biotechnol. 2011 May;12(5):758-64
pubmed: 21342121
Crit Rev Food Sci Nutr. 2014;54(5):572-9
pubmed: 24261532
Br J Nutr. 2017 Dec;118(11):971-980
pubmed: 29173199
Sci Rep. 2020 Jul 30;10(1):12849
pubmed: 32732956
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Am J Reprod Immunol. 2014 Sep;72(3):262-9
pubmed: 24807109
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Nutrients. 2019 Jan 05;11(1):
pubmed: 30621269
Life Sci. 2018 Jun 15;203:255-267
pubmed: 29715470
Arh Hig Rada Toksikol. 2007 Sep;58(3):367-74
pubmed: 17913692